GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer, Non-Small Cell

Interventions: Biological: Immunotherapeutic GSK1572932A
Drug: Cisplatin (CDDP)
Drug: Vinorelbine
Procedure: Radiotherapy

First Posted Date: 2007-04-03

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 71

Registration Number: NCT00455572

Locations: 🇬🇧
GSK Investigational Site, Southampton, United Kingdom

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

Phase 2

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Meningococcal vaccine 134612
Biological: Menactra®

First Posted Date: 2007-04-02

Last Posted Date: 2018-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 873

Registration Number: NCT00454909

Locations: 🇺🇸
GSK Investigational Site, Waipio, Hawaii, United States

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Phase 4

Completed

Conditions: Haemophilus Influenzae Type b
Neisseria Meningitidis
Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Interventions: Biological: Menitorix
Biological: Infanrix IPV

First Posted Date: 2007-04-02

Last Posted Date: 2020-06-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 288

Registration Number: NCT00454987

Locations: 🇬🇧
GSK Investigational Site, Oxford, Oxfordshire, United Kingdom

A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2007-03-29

Last Posted Date: 2018-03-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 23

Registration Number: NCT00453479

Locations: 🇳🇱
GSK Investigational Site, Zuidlaren, Netherlands

The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics

Phase 1

Terminated

Conditions: Asthma

Interventions: Drug: Placebo
Drug: GW805858

First Posted Date: 2007-03-29

Last Posted Date: 2017-09-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 31

Registration Number: NCT00453791

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients

Phase 4

Completed

Conditions: Asthma
Mild Asthma

First Posted Date: 2007-03-29

Last Posted Date: 2013-02-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 14

Registration Number: NCT00453778

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Meningococcal vaccine GSK134612
Biological: Mencevax™ACWY
Biological: Fluarix™

First Posted Date: 2007-03-29

Last Posted Date: 2018-09-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1352

Registration Number: NCT00453986

Locations: 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK233705

First Posted Date: 2007-03-29

Last Posted Date: 2017-08-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT00453687

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Drug: Fluticasone propionate 250 mcg BID

First Posted Date: 2007-03-27

Last Posted Date: 2016-12-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 621

Registration Number: NCT00452699

Locations: 🇵🇭
GSK Investigational Site, Quezon City, Philippines

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Drug: Fluticasone propionate 250 mcg BID

First Posted Date: 2007-03-27

Last Posted Date: 2016-12-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 628

Registration Number: NCT00452348

Locations: 🇵🇭
GSK Investigational Site, Quezon City, Philippines

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy